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Abstract
A substantial body of evidence implicates TGFβ as a tumor promoter in epithelial cells that have become resistant to
its tumor suppressor activity. To better understand early, genome-wide TGFβ responses in cells resistant to growth
inhibition by TGFβ, we used microarray analysis in a well-defined cell culture system of sensitive and resistant intes-
tinal epithelial cells. TGFβ-regulated gene expression in TGFβ-growth–sensitive, nontransformed rat intestinal epithe-
lial cells (RIE-1) was compared to expression in TGFβ-growth–resistant RIE cells stably transformed by oncogenic
Ras(12V). Treatment of RIE-1 cells with 2 ng/ml TGFβ1 for 1 hour increased the expression of eight gene sequences
by 2.6-fold or more, whereas eight were down regulated 2.6-fold. In RIE-Ras(12V) cells, 42 gene sequences were up-
regulated and only 3 were down-regulated. Comparison of RIE and RIE-Ras(12V) identified 37 gene sequences as
unique, Ras-dependent genomic targets of TGFβ1. TGFβ-regulation of connective tissue growth factor and vascular
endothelial growth factor, two genes up-regulated in RIE-Ras cells and previously implicated in tumor promotion,
was independently confirmed and further characterized by Northern analysis. Our data indicate that overexpression
of oncogenic Ras in intestinal epithelial cells confers a significantly expanded repertoire of robust, early transcrip-
tional responses to TGFβ via signaling pathways yet to be fully elucidated but including the canonical Raf-1/MAPK/Erk
pathway. Loss of sensitivity to growth inhibition by TGFβ does not abrogate TGFβ signaling and actually expands the
early transcriptional response to TGFβ1. Expression of some of these genes may confer to Ras-transformed cells
characteristics favorable for tumor promotion.
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Introduction
A large body of work during the past two decades has established
transforming growth factor beta (TGFβ) as a potent suppressor of
cellular proliferation in most experimental settings. Indeed, TGFβ
is now distinguished as one of the most important tumor suppressors
in human cancer biology [1–5]. Notwithstanding, for many years, it
has been clear from in vitro studies that the contribution of TGFβ
signaling to cell behavior is far more complex than negative regula-
tion of cellular proliferation. In some contexts, TGFβ may contribute
to the transformed phenotype. Several recent in vivo studies convinc-
ingly implicate TGFβ as a tumor promoter in transformed cells [6,7],
leading to the hypothesis that the tumor-promoting effects of TGFβ
increasingly predominate over growth-inhibitory effects during tu-
mor progression. It seems that overexpression of genes associated
with cellular proliferation cooperate with TGFβ to accelerate tumor
formation and metastasis, presumably after cells have become resis-
tant to TGFβ-mediated growth inhibition.
The most completely understood signal transduction pathway
used by TGFβ is the canonical Smad pathway [8–10]. Transforming
growth factor β receptor (TGFβR) activation results in serine phos-
phorylation of Smad2 and Smad3 and formation of heteromeric com-
plexes with Smad4. The Smad complex accumulates in the nucleus
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by regulated nuclear import and binds to DNA in a sequence-specific
manner in association with a large number of potential transcriptional
coactivators and corepressors [11,12]. The specificity and complex-
ity of the genomic response to TGFβ is attributable in part to the
complex portfolio of coactivators and corepressors available under
the specific conditions at the time of TGFβ exposure [3,10]. A large
number of other signal transduction pathways, including Erk kinases,
protein kinase C, Rho-like GTPases, p38, and c-Jun N-terminal ki-
nases, have been identified as apparent Smad-independent signaling
mechanisms, but activation of these depends to a significant extent
on the cell system under study [13]. At present, it is not clear if tumor
promotion by TGFβ occurs by these Smad-independent pathways or
by a modification or attenuation of Smad signaling.
In intestinal neoplasia, loss of TGFβ tumor-suppressor activity oc-
curs by a variety of well-described genetic and epigenetic defects. The
small GTPase Ras is activated by mutation in many human cancers
[14,15], including more than 50% of colorectal cancers [16]. Mul-
tiple cell culture studies have identified Ras activation as an epige-
netic factor conferring resistance to growth inhibition by TGFβ
[17]. We previously found that stable transformation of rat intestinal
epithelial cells with oncogenic Ras(12V) did not attenuate Smad lo-
calization to the nucleus in response to TGFβ treatment but caused
resistance to growth inhibition [18]. Furthermore, TGFβ activation
of Smad binding element–driven reporter gene transcription in RIE-
Ras(12V) cells was markedly reduced [19], indicating interference
with Smad-dependent transcription. Notwithstanding this loss, or
at least significant attenuation of Smad-mediated growth inhibitory
signaling in the context of oncogenic Ras, it is clear that residual,
albeit modified, TGFβ signaling continues to occur.
To examine more broadly the effects of Ras transformation on the
early genomic response to TGFβ, we used DNA microarrays to com-
pare induction of target gene transcription in nontransformed rat in-
testinal epithelial cells (RIE-1) and in cells stably transformed by Ras
(12V) [RIE-Ras(12V)] 1 hour after treatment with TGFβ1. Cellular
and specific Smad-responsive transcriptional responses to TGFβ have
been extensively characterized in these cell lines, particularly in the
context of Ras transformation [18–20]. Because growth inhibitory
Smad signaling is markedly attenuated in RIE-Ras(12V) cells, we hy-
pothesized that this apparent “resistance” to TGFβ would result in
induction of fewer early transcriptional targets in Ras-transformed
cells. However, to the contrary, we found that mutant oncogenic
Ras expands the early genomic response to TGFβ, such that more
than five times as many genes are activated in RIE-Ras(12V) cells
than parental RIE cells at a cutoff threshold ≥2.6-fold induction. Mi-
croarray analysis of TGFβ-mediated gene transcription in RIE and
RIE-Ras identifies a number of candidate genes, which may contrib-
ute to TGFβ actions as a tumor promoter, the setting of oncogenic
Ras activation. Among these candidate genes, we examined in more
detail the kinetics and signaling pathways involved in the induction
of two differentially induced genes, vascular endothelial growth factor
(VEGF ) and connective tissue growth factor (CTGF ).
Materials and Methods
Cell Lines and Reagents
RIE-1 rat intestinal epithelial cells (RIE) were obtained from Ken
Brown (Cambridge, United Kingdom) and maintained in DMEM
supplemented with 10% FCS. RIE cells are a diploid, nontrans-
formed, TGFβ-growth–sensitive cell line derived from rat jejunum
[18,20,21]. RIE-Ras cells were established by stable transfection of
the parental cells with pSV2-H-Ras(12V) that contain human se-
quences encoding the constitutively active H-Ras(12V) protein
[22]. The RIE-Ras transfectants were selected in G418 (Calbiochem,
San Diego, CA). The cell line designated RIE-Ras(12V) in this study
was established as a pooled population of stable clones and grown at
all times in the presence of 50 μg/ml G418. For each experiment,
RIE or RIE-Ras cells were plated in duplicate, grown to log phase,
and treated with 2 ng/ml of TGFβ1 (BD Biosciences, Bedford, MA)
or diluent for 1 hour, after which RNA was immediately collected.
RNA Isolation
For each array experiment, RNA was isolated from ∼107 cells
growing in log phase on four separate 10-cm2 tissue culture dishes.
RNA was isolated using Trizol (Invitrogen, Carlsbad, CA), followed
by purification with the RNEasy system (Qiagen, Valencia, CA).
Each collection yielded approximately 100 μg of RNA. RNA integ-
rity was verified using the Agilent Bioanalyzer in the Microarray Core
Facility at the Columbus Children’s Research Institute.
Probe Preparation and Array Hybridization
Complementary DNA (cDNA) probe was prepared by the Micro-
array Core Facility (Columbus Children’s Research Institute) with
Superscript III using oligo-dT primers and dNTPs supplemented
with amino-allyl-UTP to improve hybridization characteristics and
stability. The DNA samples were labeled with Cy3 or Cy5 then were
purified. Purified probe was hybridized to the Agilent Rat Olio Mi-
croarray (Agilent, Cincinnati, OH) for 14 hours at 48°C according to
the manufacturer’s protocol. This array (Agilent G4130A) is com-
posed of 20,500 rat genes, ESTs, and EST clusters printed on a glass
slide as 60-mers. The gene list can be downloaded from www.agilent.
com. Slide images were acquired using an Affymetrix 428 scanner
with gain settings set so that 95% of spots were below saturation
to yield the maximum dynamic range within an experiment. Images
were converted into “.gpr” files using GenePix software (Axon,
Union City, CA). Image files (.tif ) were deposited onto the Gene Ex-
pression Omnibus Web site (http://www.ncbi.nlm.nih.gov/geo) with
the Series Accession Number GSE2015.
Data Analysis
Four independent experiments from cell culture to chip hybridiza-
tion were performed for both RIE and RIE-Ras. Data were analyzed
using GeneTraffic 2.6 software (Iobion, La Jolla, CA). Lowess-global
normalization was applied to all experiments. Flagging parameters
were set as spot intensity lower than the intensity of local spot back-
ground, spot intensity lower than average background, and raw spot
intensity less than 100. Flagged spots were not included in normal-
ization or aggregate calculations. Only genes that were induced or
repressed at a level of log2N > 1.4 (2.6-fold) in at least three of
the four independent analyses and hybridizations were identified as
TGFβ-regulated genes. The NIA Array Analysis Tool (http://lgsun.
grc.nia.nih.gov) was used to determine the false discovery rate
(FDR), which is equivalent to a P value in experiments with multiple
hypothesis testing. The maximum FDR was set at .05. The NIA
Array Analysis Tool was also used to determine the correlation coef-
ficient matrix for each of the RIE and RIE-Ras experiment sets.
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Real-time Polymerase Chain Reaction and
Northern Blot Analysis
Real-time polymerase chain reaction (PCR) andNorthern blot anal-
ysis was used with a selected set of genes to verify results of the array
experiments. RNA from two independent samples used to generate
probes for the array experiments was used to generate cDNA for the
real-time PCR reactions. First, 1 μg of total RNA was converted to
cDNA using SuperScript II RT (Invitrogen). Serial 10-fold dilutions
of the cDNA were used for each primer set in triplicate. Polymerase
chain reaction reactions were carried out in 96-well plates with the
with SybrGreen Taq polymerase (ABI, Foster City, CA) according to
standard protocol with an ABI 7700 Sequence Detector machine.
Primer sequences were determined using PrimerDesigner software
(ABI) with published GenBank sequences. Cyclophilin and GAPDH
were used as controls, and results are reported as ΔΔC t relative to
GAPDH. For each experiment, theΔC t was determined by the average
of three identical samples. The values in Figure 1 represent the
average ΔΔC t from two independent experiments. Primer sequences
are listed below:
 APC2-F: 5′-CGCTTCGGTACCTCAGACGA
 APC2-R: 5′-TGTCAATCTGCTCCAGGCG
 BHLHB2-F: 5′-CTGCCCAAAACGCCAGG
 BHLHB2-R: 5′-CACTTGGTACATGTGGGCAAA
 CYCLOPHILIN D-F: 5′-GGCCATGTATCCTTAGCAAG-
TGTC
 CYCLOPHILIN D-R: 5′-GGTCAGCATTGCCGATGTC
 ERBIN-F: 5′-CACTCTGTGGCACCCTAAACAA
 ERBIN-R: 5′-CTGCACTCTCAGATCTTGGAGG
 FMR2-F: 5′-TGGTTTTTCCACAGTTATGGCA
 FMR2-R: 5′-CTGCAAAGACAGACCACCACAA
 GADD45B-F: 5′-ACTCCCCTCTCCTCGTCTCAG
 GADD45B-R: 5′-CTCAAAAGCTACCCTACCCGTG
 GADD45G-F: 5′-CCAGTCCAGGCGGCC
 GADD45G-R: 5′-GTGACTCAGCAAGCAGCCTTC
 GAPDH-F: 5′-ACAAGATGGTGAAGGTCGGTGT
 GAPDH-R: 5′-CAAGAGAAGGCAGCCCTGG
 JUNB-F: 5′-GAGGAGCAGGAGGGCTT
 JUNB-R: 5′-TCACGTGGTTCATCTTCTGCAG
 LRF-F: 5′-TGTGCCACAGTGCGGC
 LRF-R: 5′-GCACGGAAGTTCTTGCAGC
 LY94-F: 5′-GGGATCACACAGCCCAGAAT
 LY94-R: 5′-CAAAAGCCATACTAGAGCCATCAC
 SMAD7-F: 5′-GCGAAAGTGGGTACCACCTTC
 SMAD7-R: 5′-ATTCACGTACACCCCCCTCA
 SNON-F: 5′-GATCGTGAAGTCGCCCAAGA
 SNON-R: 5′-AGTCCTGCCAACCAAACACAG
 VEGF-F: 5′-GCCCTGGAGTGCGTGC
 VEGF-R: 5′-GTGAGGTTTGATCCGCATGA
Northern Blot Analysis
To generate nucleotide probe for FMR2 sequence, cDNA was first
generated from RIE mRNA according to a standard protocol using
Superscript II Reverse Transcriptase (Invitrogen). An FMR2 DNA
probe was generated by amplification of FMR2 sequence using
probes (FMR2F and FMR2R) designed to amplify from nucleotide
1250 to 1531 of the sequence published with the accession number
XM_219832 using an annealing temperature of 60°C. RIE and RIE-
Ras cells were treated with 2 ng/ml TGFβ (BD Biosciences) from 0
to 24 hours, and RNA was isolated using Trizol (Invitrogen) with
subsequent purification using the Qiagen RNEasy kit (Qiagen).
Total RNA samples (1 mg per lane) were run on agarose gels, then
blotted onto Hybond-XL (Amersham, Piscataway, NJ) membrane,
which was hybridized with the 281-bp 32P-labeled FMR2 probe.
The membrane was then washed and exposed to film, scanned, and
Figure 1. Real-time PCR of TGFβ target genes identified by DNA array. The change in gene expression of genes in RIE-Ras(12V) cells
treated for 1 hour with 2 ng/ml TGFβ1 is shown by the results from the array experiments as well as by real-time PCR experiments. The
average change in gene expression determined by the four independent array experiments is shown in light gray. Real-time PCR was
used with a selected set of genes to verify the results of the array experiments. The ΔΔCt for the genes relative to GAPDH represents
fold-change after TGFβ treatment, shown in black. GAPDH and cyclophilin are housekeeping genes, the expression of which did not
change significantly with TGFβ1 treatment. The genes identified by the array experiments as having increased transcription in RIE-Ras
(12V) cells after TGFβ1 treatment were confirmed by real-time PCR experiments.
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signal was quantitated with ImageQuant TL Image Analysis software
(Amersham). The FMR2 PCR probes were as follows: FMR2F: 5′-
TGCAAAGACAGACCACCACAA-3′; FMR2R: 5′-AAAGTG-
CGGGAGGGAACAG-3′.
For the expression of VEGF and CTGF, total cellular RNA was
extracted using Trizol. RNA samples (20 μg per lane) were loaded
into 1% agarose/formaldehyde gels, separated by electrophoresis,
and blotted onto nitrocellose membranes. VEGF (a kind gift from
Dr. Robert Coffey) and CTGF (a kind gift from Dr. David Brigstock)
cDNAprobes were labeled by random primer extension using Redivue
with α-32 P-dCTP and the Rediprime DNA labeling system from
Amersham Life Sciences (Arlington Heights, IL). After hybridization
and washing, the membranes were subjected to autoradiography. In-
tegrity and loading of the RNA samples were assessed by 18 rRNA
signals or expression of cyclophilin, a constitutively expressed mRNA.
For VEGF, mRNA results were confirmed by ELISA (VEGF Quanti-
kine Kit; R&D Systems, Minneapolis, MN).
Results
Early Genomic Responses to Short-term TGFβ
Exposure in RIE Cells
DNA microarray was used to quantitatively and qualitatively as-
certain TGFβ1-regulated gene expression in RIE cells that are sensi-
tive to growth inhibition by TGFβ and RIE cells stably transformed
with oncogenic Ras(12V) that are resistant to growth inhibition by
TGFβ [18]. We intentionally focused on early genomic responses be-
cause these most likely reflect the primary alterations in TGFβ sig-
naling conferred by the expression of oncogenic Ras. Similarly, we
imposed a stringent definition of a TGFβ1 target to identify as pure
a profile of targets as possible.
The Agilent Rat Oligo microarray glass slide system was used to
compare expression of 20,500 genes in each cell line at baseline and
1 hour after exposure to 2 ng/ml TGFβ1. Significantly regulated
genes were defined by a minimum change in expression of log2N =
1.4 (2.6-fold) in at least three of the four array slides used for each
cell line. Data tables for all real genes on the Agilent Rat Oligo chip
for each of the four independent experiments from both the RIE and
RIE-Ras cell lines are included in Supplemental Data. Data including
fold change and log ratios are also available on the Gene Expression
Omnibus Web site (http://www.ncbi.nlm.nih.gov/geo) with the Se-
ries Accession Number GSE2015. Reproducibility of the data from
the individual array slides was verified using the NIA Array Analysis
Tool, and correlation coefficients are shown in Table 1.
In RIE cells, eight genes were up-regulated by TGFβ, and eight
genes were down-regulated. In RIE-Ras(12V) cells, 42 genes were
up-regulated and 3 genes were down-regulated (Table 2, A–D). Of
the 42 genes up-regulated by TGFβ in RIE-Ras(12V) cells, 5 were
also up-regulated in RIE cells, all of which have previously been de-
scribed as transcriptional targets of TGFβ: GADD45β [23], VEGF
[24], junB [25], BHLHB2 [26], and Smad7 [27]. In our experiments,
37 transcripts were uniquely up-regulated in RIE-Ras cells. Of these,
seven have unknown functions. The remainder fall into diverse func-
tional clusters including genes whose products function as proteases
(n = 3), transcription factors (n = 4), structural proteins (n = 5), cell
cycle regulators (n = 1), cell signaling factors (n = 5), regulator of
cell-mediated immunity (n = 1), and proteins with other cellular
functions (n = 11). These Ras-specific genes are ideal candidate
pro-oncogenic genes that contribute to TGFβ-mediated tumor pro-
gression and metastasis [1].
Confirmation of TGFβ-Regulated Gene
Expression by mRNA Analysis
Eleven genes up-regulated by TGFβ1 treatment of Ras-transformed
cells were selected for confirmation by real-time PCR because they
were prominently regulated or were putative tumor promoters. In
each instance, genes identified as transcriptional targets of TGFβ1
by microarray were similarly up-regulated when tested by real-time
PCR (Figure 1). Several of the genes induced in both the RIE (5/8)
and RIE-Ras(12V) (10/42) cells have been identified as TGFβ-
induced genes in previous studies (Table 2), further supporting the
validity of our results. The differential expression of FMR2 was inde-
pendently confirmed by a more extensive time course using Northern
blot analysis. These results were also consistent with the results from
the array experiments and were particularly interesting because ex-
pression was regulated in a binary fashion, being up-regulated in
RIE-Ras cells treated with TGFβ1 and down-regulated in the parental
cell line (Figure 2).
Regulation of VEGF and CTGF Expression by
TGFβ in RIE-Ras Cells
Two genes, VEGF and CTGF, were selected for more intensive
study because they were markedly induced in Ras-transformed RIE
cells, they are abundantly expressed, and they are well known as
TGFβ-induced genes. VEGF has been implicated as a potential con-
tributor to the pro-oncogenic activities of TGFβ [5,28]. Northern
blot analysis (Figure 3A) and signal quantification (Figure 3B, right
panel ) of an expanded time course of VEGF mRNA expression in
intestinal epithelial cells lines show a fivefold induction in the
TGFβ-growth–resistant, transformed RIE-Ras cell line as opposed
to a twofold induction in the parental cell line. This more robust
increase in Ras-transformed RIE-1 cells occurs despite a basal level
of VEGF expression in RIE-Ras cells that significantly exceeds that
in the RIE cells (Figure 3B, right panel). Similar observations were
made for the VEGF protein measured by ELISA, again showing a
more prominent induction of VEGF by TGFβ in the RIE-Ras cell
line (Figure 3C ). As prior work has found significantly reduced
Smad-mediated transcription in Ras-transformed RIE cells [19,20],
it is highly unlikely that TGFβ induction of VEGF in these cells
occurs exclusively by Smad-dependent signaling. In support of this
assertion, VEGF mRNA expression was also significantly induced
in two human colon cancer cell lines, HT-29 and SW620, both of
which have defective Smad-dependent signaling (not shown).
The potential contribution of alternate, Smad-independent signal-
ing pathways in TGFβ-mediated VEGF induction was examined by
Table 1. Correlation Coefficient Matrices.
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Table 2. Up-regulated and Down-regulated TGFβ-Responsive Genes in RIE and RIE-Ras Cells.
Name Accession Number log2(N ) FDR Function
(A) RIE-Ras: up-regulated
Unknown AI599739 2.86 .000 Unknown
GADD45β* CA509894 2.64 .000 Cdc2/cyclin B1 kinase inhibitor
Unknown BE117708 2.48 .000 Unknown
Bile acid CoA ligase NM_024143 2.39 .001 Conjugates bile acid with amino acid
Endothelial differentiation, sphingolipid
G-protein–coupled receptor, 3
BF281109 2.26 .000 G-protein–coupled receptor with putative role in angiogenesis
Adenomatosis polyposis coli 2 CB547568 2.24 .000 Homolog of tumor-suppressor APC, with putative roles in transcription and signal transduction
C1q-related factor AI716054 2.07 .000 Unknown
Sciellin AI717110 2.05 .002 Structural protein
Lymphocyte antigen 94 NM_057199 2.03 .017 Lysis receptor of NK cells
Thyroglobulin* NM_030988 1.95 .000 Catalyzes formation of thyroid hormone
Calcyon NM_138915 1.9 .000 Membrane protein that interacts with dopamine receptor
Thrombospondin* BE127095 1.87 .000 Extracellular matrix protein with putative role in angiogenesis
Fragile X mental retardation 2* CB546478 1.85 .000 Putative transcription factor
Erbb2 interacting protein CB546222 1.83 .000 Inhibit EGF signaling by preventing the activation of the Raf-1 kinase by Ras
Down syndrome cell adhesion molecule NM_133587 1.72 .000 Ig superfamily cell-adhesion molecule thought to function in neuronal development
Unknown (serine/threonine kinase domain) AW527300 1.7 .000 Unknown
Isopeptidase T-3 AW521619 1.69 .000 Ubiquitin-specific protease
Jun B proto-oncogene* NM_021836 1.69 .000 AP-1 family transcription factor
Basic helix-loop-helix domain containing, class B2* NM_053328 1.68 .000 Transcription factor
MAD homolog 7* NM_030858 1.68 .000 Inhibits Smad3/Smad4 signaling
FLJ00179 protein BG673684 1.66 .000 Unknown
Myosin binding protein H NM_031813 1.66 .014 Structural protein involved in myosin binding
Hypothetical C2H2 zinc finger protein CB546651 1.65 .000 Putative transcription factor
Plasminogen activator inhibitor type 11 NM_012620 1.62 .000 Major inhibitor of plasminogen activators
Gb3 synthase NM_022240 1.62 .004 Catalyzes glycosphingolipid synthesis
Receptor type protein tyrosine phosphatase psi U66566.1 1.6 .000 Transmembrane receptor–type protein tyrosine phosphatase with putative role in
neuronal development
Neuraminidase 1 NM_031522 1.59 .000 Removes sialic acids from glycoproteins and gangliosides
Preproprolactin-releasing peptide NM_022222 1.56 .000 Stimulates stress hormone secretion by either direct pituitary or indirect hypothalamic actions
Leukemia/lymphoma–related factor CB546785 1.54 .000 Zing finger transcription factor
Tenascin XB CB544736 1.54 .000 Extracellular matrix glycoprotein
Connective tissue growth factor* NM_022266 1.53 .000 Matricellular protein that plays an essential role in the formation of blood vessels, bone, and
connective tissue
Unknown function CB544526 1.52 .000 Unknown
Unknown function AI409493 1.47 .000 Unknown
Ski-related novel protein N* CB548407 1.46 .000 Smad 2/Smad 3 repressor
Hypothetical intermediate filament proteins
containing protein
BM389145 1.45 .002 Putative structural protein in cytoskeleton or nuclear envelope
GADD45γ* BF419904 1.45 .000 Cdc2/cyclin B1 kinase inhibitor
Olfactory protein M64376.1 1.45 .004 Seven transmembrane domain protease
Eferin CB545653 1.45 .032 ADP-ribosylation factor binding protein of unknown function
45-kDa secretory protein AJ132352.1 1.44 .000 Lipid binding protein of unknown function
Activator of G-protein signaling 3 NM_144745 1.43 .001 Guanine nucleotide dissociation inhibitor that contains G protein regulatory motifs in its
C-terminal domain
Vascular endothelial growth factor* NM_031836 1.4 .000 Vascular growth factor
(B) RIE-Ras: down-regulated
S100A6 NM_053485 −2.38 .000 Calcium binding protein of unknown function
Cadherin 15 CB544279 −2.15 .020 Cell-cell adhesion molecule
Stomatin-like 1 CB544301 −1.39 .049 Putative sterol-binding protein
(C) RIE: up-regulated
MAD homolog 7* NM_030858 2.16 .000 Inhibits Smad3/Smad4 signaling
GADD45β* CA509894 2.03 .000 Cdc2/cyclin B1 kinase inhibitor
Basic helix-loop-helix domain containing, class B2* NM_053328 1.87 .000 Transcription factor
Unknown CB545096 1.77 .002 Unknown
Vascular endothelial growth factor* NM_031836 1.64 .000 Vascular growth factor
Jun B proto-oncogene* NM_021836 1.55 .004 AP-1 family transcription factor
Hairy and enhancer of split 1 NM_024360 1.4 .000 Notch pathway homeobox transcription factor
Unknown CB546780 1.4 .000 Zinc finger domain, unknown function
(D) RIE: Down-regulated
Nuclear distribution gene C homolog NM_017271 −2.04 .000 Regulates movement of nuclei after mitosis
Ribosomal protein L27 NM_022514 −1.9 .001 Ribosomal protein
Ribosomal protein S29 NM_012876 −1.83 .004 Ribosomal protein
Glutathione S-transferase P subunit NM_138974 −1.7 .002 Component of glutathione S -transferase
Helicase DDX32 CB548436 −1.59 .006 DEAH family helicase
Hypothetical protein FLJ12800 BE106894 −1.56 .009 Unknown
Fragile X mental retardation 2* CB546478 −1.5 .017 Putative transcription factor
Unknown BF390720 −1.45 .000 Putative component of Golgi complex
*Previously identified as TGFβ-regulated.
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use of specific small molecule inhibitors. Inhibition of the p38
MAPK pathway and the phosphoinositol 3-kinase pathway, two sig-
naling cascades previously implicated in Smad-independent responses
to TGFβ [13,29], did not attenuate induction of VEGF by TGFβ1
(Figure 3D). Inhibition of MAP kinase kinase (MEK) with U-0126
and Raf-1 kinase with BAY-439006 blocked induction of VEGF
by TGFβ, implicating TGFβ activation of Raf-1/Erk signaling as a
potential Smad-independent pathway for TGFβ signaling in Ras-
transformed RIE-1 cells. Interestingly, in the setting of Raf-1 kinase
inhibition, levels of VEGF were not further increased by TGFβ1, but
basal levels of VEGF were elevated above control.
The role for CTGF in tumorigenesis is not clear, but in certain
cellular contexts, CTGF is a pro-oncogenic, profibrogenic growth fac-
tor [30]. It is tumor-suppressive in other contexts [31]. CTGF is also
frequently identified as a prominently regulated gene in genomic
profiles of TGFβ action [32,33] a finding that we confirm herein.
CTGF expression was also differentially and prominently up-regulated
in RIE-Ras cells, with maximal expression 31-fold above basal levels
occurring 2 hours after treatment with TGFβ in RIE-Ras cells com-
pared with a 3.5-fold induction in the parental RIE-1 line (Fig-
ure 4A). CTGF expression was also robustly induced in HT-29
cells, a Smad4-deficient human colon carcinoma cell line that is
resistant to growth inhibition by TGFβ (not shown), implying
Smad independence. Figure 4B shows markedly reduced basal levels
of CTGF in exponentially growing RIE-Ras(12V) cells compared
with the parental line. The original of this differential expression
is being explored separately. In contrast to the involvement of the
canonical MAPK pathway in VEGF induction by TGFβ in Ras-
transformed cells (Figure 3A), induction of CTGF was not blocked
by inhibitors of the p38 MAPK, phosphoinositol 3-kinase, MEK,
or Raf-1 kinase pathways (Figure 4C ). Thus, the Smad4-independent
signaling pathway responsible for TGFβ induction of CTGF in Ras-
transformed intestinal remains unclear.
Discussion
Until recent years, the pro-oncogenic effects of TGFβ could only
be indirectly inferred [34–36] from studies that describe increased
TGFβ levels in metastatic tumors [37,38] or report increased expres-
sion of TGFβ as a risk factor for recurrence and reduced survival [39].
For instance, colorectal cancers with mutant, inactivated TGFβRII
have presumably no potential for pro-oncogenic signaling and a
prognosis that is better than cancers with retention of one allele
[40]. Conversely, restoration of TGFβRII expression in cells that
carry a mutation in this gene increases cell invasiveness in vitro
[35]. Thus, once tumors escape growth regulation by TGFβ, if
the potential remains for residual TGFβ signaling, the result is
an enhanced potential for tumorigenesis. Furthermore, the apparent
duality of TGFβ signaling has been observed in vivo; in bitrans-
genic mice, mutant activated TGFβ is associated with delayed tumor
onset in early stages, whereas in later stages, it leads to an increase in
metastatic foci [7,41].
It is clear that oncogenic events such as transformation by mutant
activated Ras may “adversely” interact with growth inhibitory TGFβ
signaling. In Ras-transformed cells, loss of an autocrine growth-
inhibitory GFβ signaling occurs coincident with a synergistic stimu-
lation of angiogenic molecules [42], matrix molecules [43], and
epithelial to mesenchymal transition [35], each of which is believed
to be important for tumor growth and metastasis in vivo. Inducible
Ras in an in vitro model using the same rat intestinal epithelial cell
line used in our current study conferred characteristics, such as inva-
siveness, consistent with tumor promotion and metastasis [44]. Ras
Figure 2. RIE and RIE-Ras Northern blots show differential expression of FMR2 in response to TGFβ1. The RIE gene expression array
showed inhibition of FMR2 expression after 1 hour of incubation with 2 ng/ml TGFβ1, whereas the RIE-Ras(12V) array showed activation
of FMR2 gene expression. These findings were supported by Northern blot analysis of FMR2 gene expression as shown in the top
panel. In the middle panel, equivalent RNA loading was confirmed verified by ethidium bromide staining of 18 and 28S ribosomal
RNA. RNA induction by TGFβ1 was quantified by scanning the autoradiographs and analyzing band intensity with densitometry (bottom
panel). Results from these Northern blots are consistent with FMR2 expression results obtained in the microarray experiments and
show a marked differential effect on FMR2 expression, with 11-fold maximal induction in Ras-transformed cells and a fourfold repres-
sion in the parental cell line. In these graphs, band intensity is reported as the signal at any given time point relative to the signal of the
control RNA or “0 hour” sample.
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overexpression also activates transcription of the TGFβ1 gene [45].
Increased levels of TGFβ in this context may further contribute to
tumor-promoting signaling in growth-resistant cells.
In the present study, we found that oncogenic Ras confers to TGFβ
a significant gain of robust early genomic responses in cultured rat in-
testinal epithelial cells that are resistant to growth inhibition. Although
we found five immediate transcriptional targets of TGFβ activated in
both RIE and RIE-Ras(12V) cells, a larger number of genes are up-
regulated by TGFβ only in the context of Ras activation. These find-
ings imply a model in which Ras-dependent TGFβ early genomic
targets may be responsible for pro-oncogenic activities of TGFβ and
potentially contribute to resistance to growth inhibition as well.
The well-recognized reduction of Smad-dependent signaling that
is characteristic of Ras-transformed epithelial cells [19,20,46,47] in-
dicates that the expanded genomic response to TGFβ occurs by an as
yet unidentified Smad-independent pathway or by an unrecognized
modification or interaction with the canonical Smad signaling path-
way. Several published reports compare transcriptional responses in
epithelial cell lines that are sensitive and resistant to growth inhi-
bition by TGFβ [32,48]. The conflicting findings in the aforemen-
tioned reports, both of which examined the consequences of silenced
Smad4 on TGFβ-mediated gene expression, serve to further under-
score the complexity of TGFβ signaling and reinforce the necessity
for further investigation.
Although our own experimental approach was not designed to spe-
cifically determine functional profiles of genes induced by TGFβ1, it
is unexpected that the GADD45β, a gene product generally associ-
ated with apoptosis and cell cycle arrest, was prominently induced in
both TGFβ-growth–sensitive parental cells and growth-resistant Ras-
transformed cells (Table 2), again emphasizing the complexity and
intricacy of TGFβ signaling. Transforming growth factor β also regu-
lates distinct genomic profiles in HaCaT cells with Smad2 and Smad3
individually attenuated by specific antisense molecules [49].
In a similar study examining transcriptional responses in a control
cell line versus a Ras-transformed line, Chen et al. [33] found that
four of the five genes up-regulated in our studies of RIE and RIE-
Ras(12V) cells were also up-regulated by TGFβ exposure for 2 to
4 hours in a nontumorigenic mammary cell line (MCF-10A) that
is sensitive to growth inhibition by TGFβ. Those same four genes
were also up-regulated by TGFβ in MCF-10A cells dually trans-
formed with activated c-Ha-ras and c-erbB2, as well as in a human
breast cancer cell line with hyperactive Ras (MDA-MG-231) both of
Figure 3. Induction of VEGF by TGFβ in RIE and RIE-Ras(12V) cells. (A) Northern blots were prepared from RNA isolated from RIE and
RIE-Ras(12V) cells treated with 2 ng/ml of TGFβ1 for the time intervals shown and probed for VEGF expression. Equivalent loading was
confirmed by the signal intensity of IB15 (cyclophilin) a constitutively expressed gene. In (B), basal expression of VEGF is shown in RIE
and RIE-Ras(12V) cells, confirming markedly increased basal expression in the Ras-transformed line. The bottom right shows densito-
metric values obtained from the Northern shown in the top panel with expression shown as a fold change overexpression at time 0. As
shown in (C) VEGF protein was also differentially induced in RIE-Ras(12V) cells. Whole-cell protein lysates were obtained from RIE-1 and
RIE-Ras(12V) cells treated with TGFβ for 24 hours. VEGF protein was quantified by ELISA, as described in the Materials and Methods
section. (D) Effect of signaling pathway inhibitors on induction of VEGF by 2 ng/ml TGFβ1. Cells were treated with 10 μM SB203580 (p38
kinase inhibitor), 10 μM U0126 (a MEK inhibitor), 1 μM RafKI (BAY-439006, a Raf-1 kinase inhibitor), and 20 μM LY294002 (phospho-
inositol 3-kinase inhibitor) for 24 hours and then treated with 2 ng/ml TGFβ1 for 1 hour before isolation of RNA according to procedures
described in the Materials and Methods section. Equivalent loading was confirmed by hybridization with a cDNA probe complementary
to cyclophilin. The results shown are representative of three separate experiments.
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which are resistant to growth suppression by TGFβ [33]. The relative
magnitude of the genomic response was not provided in the report
by Chen et al, except to allude to the fact that many responses were
generated in the Ras-transformed lines. These results, along with
others [50,51], indicate that despite resistance to TGFβ growth in-
hibition, transformed epithelial cell lines from multiple epithelial
lineages retain at least some common TGFβ transcriptional targets
as well as an expanded repertoire of genomic responses. Thus, the
results observed in the present study and others reported to date seem
to be generalizable.
Individual Ras-specific, TGFβ up-regulated genes identified in our
study have been implicated in tumor progression. For example, plas-
minogen activator inhibitor type 1 (PAI-1) is up-regulated in human
cancer and correlates with metastatic behavior [52]. Thrombospondin
and VEGF are associated with angiogenesis and metastasis (reviewed
in Bergers and Benjamin [53]). The ErbB2-interacting protein (Erbin)
is a PDZ domain-containing protein that binds the C-terminus of
ErbB2 that is essential for epithelial integrity. Recent studies show that
Erbin suppresses Ras activation of Erk signaling while preserving acti-
vation of other Ras effectors such as Akt. A recent expression profile of
genes expressed in breast cancer includes Erbin as a “poor prognosis”
marker [54].
A homolog of the tumor-suppressor gene adenomatosis polyposis
coli (APC), APC2, was also specifically up-regulated in the RIE-Ras
(12V) cell line. APC1 and APC2 have overlapping roles in Wingless
pathway signaling in Drosophila and mice [55]. Loss of expression of
APC has been associated with most sporadic colon adenocarcinomas
leading to overactivation of the Wingless/Wnt signaling pathway
(reviewed in Grady and Markowitz [56]). It is not clear how over-
expression of APC2 might contribute to tumorigenesis; however,
its expression has recently been found to be up-regulated in lung ad-
enomas and lung adenocarcinomas compared to normal lung [57].
Neither APC nor APC2 has previously been identified as a transcrip-
tional target of TGFβ.
An intriguing finding in our analysis is that fragile X mental retar-
dation gene 2 (FMR2) was among the most repressed genes in RIE
cells and among the most activated in RIE-Ras(12V) cells. Northern
blot analysis of FMR2 expression at multiple time points verified the
finding of the array that FMR2 is induced by TGFβ in RIE cells and
is inhibited in RIE-Ras cells (Figure 2, A and B). FMR2 was origi-
nally cloned in an attempt to identify the basis for FRAXE-linked
mental retardation. Subsequent analysis localized FMR2 to the nu-
cleus and identified it as a transcriptional activator (reviewed in Gu
and Nelson [58]). LAF4, an FMR2 family member, was identified
through chromosomal translocations that resulted in Burkitt lym-
phoma [59]. Rearrangements of LAF4, as well as two other FMR2
family members, AF4 and AF5q21, with the mixed leukemia lineage
(MLL) gene have been identified in infant acute lymphoblastic leuke-
mia, indicating that this gene family may have a function in cell pro-
liferation and oncogenesis [60–62]. Lilliputian, an FMR2 Drosophila
homologue, is involved in both TGFβ [63] and Erk signaling [64],
which is intriguing in light of our observation that FMR2 expression
was repressed by TGFβ in RIE cells and induced by TGFβ in the set-
ting of oncogenic Ras. The role of this gene in the cellular response to
TGFβ merits further study.
VEGF and CTGF expression in response to TGFβ exposure was
examined in more detail in our study. These genes are more robustly
regulated in RIE-Ras cells than the parental line, raising the impor-
tant question of the signaling mechanics involved. Because Smad-
dependent signaling is attenuated in Ras-transformed RIE cells [19],
it is unlikely that this pathway accounts for the accentuated expression
of these TGFβ-inducible genes. Our results indicate that activation of
the canonical Raf-1/MAPK/Erk pathway may contribute to VEGF
but not CTGF induction. Additional candidate pathways deserve fur-
ther exploration.
In summary, ours is the first study designed to identify and charac-
terize the TGFβ-induced transcriptome in intestinal epithelial cells
transformed by oncogenic Ras. Despite the attenuation of Smad-
dependent, growth-inhibitory signaling in intestinal epithelial cells
that overexpress oncogenic Ras, TGFβ induces a significantly ex-
panded repertoire of highly regulated (≥2.6-fold induction) genomic
targets in these cells. This finding is analogous to other existing work
that shows an expanded genomic profile when specific components of
the Smad pathway are abrogated. The biologic properties of many of
these TGFβ-induced genes are consistent with a tumor-promoting
role for TGFβ and deserve further scrutiny as pro-oncogenic factors.
Figure 4. Induction of CTGF by TGFβ in RIE and RIE-Ras(12V) cells.
(A) Northern blots were prepared from RNA isolated from RIE and
RIE-Ras(12V) cells treated with 2 ng/ml of TGFβ1 for the time inter-
vals shown and probed for CTGF expression. Equivalent loading
was confirmed by the signal intensity of IB15, a constitutively ex-
pressed gene. (B) Relative expression of CTGF in RIE and RIE-Ras
(12V) cells shows markedly reduced basal expression in the Ras-
transformed line. Equivalent loading is confirmed by expression of
1B15, a constitutively expressed RNA species. (C) Organized iden-
tically to Figure 3D, and the RNA samples were identical to those
used in Figure 3D. Cells were treated with 10 μM SB203580 (p38
kinase inhibitor), 10 μM U0126 (a MEK inhibitor), 1 μM RafKI (BAY-
439006, a Raf-1 kinase inhibitor), and 20 μM LY294002 (phospho-
inositol 3-kinase inhibitor) for 24 hours and then treatedwith 2 ng/ml
TGFβ1 for 1 hour before isolation of RNA according to procedures
described in theMaterials andMethods section. Equivalent loading
was confirmed by hybridization with a cDNA probe complemen-
tary to cyclophilin. The result shown is representative of three sep-
arate experiments.
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A critical consideration is the extent to which this unique transcrip-
tome occurs because of Smad-independent signaling, Smad signaling
that is modified in an unrecognized manner by hyperactive Ras activ-
ity, or both.
Supplemental Data
Raw Data
Raw image files (.tif ) for each experiment are available at the Gene
Expression Omnibus Web site (http://www.ncbi.nlm.nih.gov/geo)
with the Series Accession Number GSE2015. These images are the
original chip scans used to generate the data in this study.
Complete Data Tables
Data tables are listed as RIE versus RIE-TGFβ × 1 hour and RAS
versus RAS-TGFβ (for the RIE-Ras experiments), each with work-
sheets #1 to #4 corresponding to results from experiments #1 to 4.
The tables summarize results including raw signal intensity from
each channel (Lex.R corresponds to control, Lex.E corresponds to
experimental), raw signal intensity with background subtracted,
normalized signal intensity, fold change (experimental/control), flag
status, Agilent gene description, Agilent probe identification, and
GenBank Accession Number. Results are listed in ascending order of
Agilent probe identification. Control spots on the Agilent Rat Oligo
chip (Agilent G4130A) not corresponding to sequence from real genes
were excluded from the table. Data including fold change and log
ratios are also available at the NCBI GEO Web site (http://www.
ncbi.nlm.nih.gov/geo) with the Series Accession Number GSE2015.
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